Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
Christine DeutschmannRupert BartschChristian F SingerDaphne Gschwantler-KaulichMichael SeifertCarmen LeserMaximilian MarholdZsuzsanna Bago-HorvathGeorg PfeilerPublished in: BMC cancer (2022)
The present study showed a considerably shorter PFS (3.0 vs. 7.5 months) and OS (8.94 vs. 25.0 months) than IMpassion130 putatively owing to the use of atezolizumab in later treatment lines, more aggressive tumors and a study population with higher morbidity compared to the pivotal trial.
Keyphrases
- locally advanced
- metastatic breast cancer
- rectal cancer
- squamous cell carcinoma
- neoadjuvant chemotherapy
- radiation therapy
- phase ii study
- clinical trial
- study protocol
- phase iii
- randomized controlled trial
- advanced non small cell lung cancer
- replacement therapy
- smoking cessation
- epidermal growth factor receptor
- chemotherapy induced
- placebo controlled